secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-01-30T23:59:59+00:00
Accession:  0001396814-25-000022
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences appoints Laura Brege as Board Chair; two directors retire
----------------------------------------------------------------------------

- Paul J. Hastings (former Chair) and Andreas Wicki retired effective Jan. 28, 2025; no disagreement cited.
- Laura Brege appointed Chair; brings 30 years pharma/biotech executive experience.
- Board reduced from 12 to 9 directors; 8 of 9 are independent; 5 joined since Oct. 2023.
- Alethia Young succeeds Brege as Audit Committee Chair; other committee assignments refreshed.
- Brege previously held leadership roles at BridgeBio, Onyx Pharmaceuticals, and COR Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000022/0001396814-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000022/pcrx-20250128.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer